Citations

Clear

3042 citation(s) found for "Kumar, S".

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
Kirkwood, Amy A. , Yohannan, Binoy , Theodorakakou, Foteini , Weverling, Flores , Simone, Valeria Di , Kumar, Shaji , Petropoulos, Ιoannis , Cohen, Oliver , Stamatelopoulos, Κimon , Whelan, Carol , Venneri, Lucia , Fontana, Marianna , Mahmood, Shameem, Schwotzer, Rahel , Wechalekar, Ashutosh , Khwaja, Jahanzaib , Milani, Paolo , Yohannan, Binoy , Theodorakakou, Foteini , Weverling, Flores , Di Simone, Valeria , Kumar, Shaji K , Petropoulos, Ioannis , Mussinelli, Roberta , Oerlemans, Marish I F J , Muchtar, E , Stamatelopoulos, Kimon , Gertz, Morie A , Fontana, Marianna , Minnema, Monique C , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios , Wechalekar, Ashutosh D. , Gillmore, Julian D , Milani, Paolo , Ravichandran, Sriram , Mussinelli, Roberta , Oerlemans, Marish I.F.J. , Muchtar, Eli , Lachmann, Helen J. , Gillmore, Julian D. , Briasoulis, Αlexandros , Gertz, Morie A. , Dispenzieri, Angela , Palladini, Giovanni , Kastritis, Efstathios

Mayo Clinic

Journal of Clinical Oncology | December 7, 2025 | Volume: 44 | Issue: 4 | Pages: 311-320

10.1200/jco-25-02558 | PMID 41353737 Get It

PURPOSE Outcomes in systemic light chain (AL) amyloidosis have improved with modern therapy limiting utility of existing risk stratification models. We validate a new staging system, incorporating longitudinal strain (LS) to the biomarker-based (NT-proBNP and Troponin-T) staging system in the contemporary treatment era (2015-2024). METHODS AL International Staging System (AL-ISS) was derived from a cohort of patients with AL amyloidosis from the UK National Amyloidosis Centre (2015-2019). The model was validated in patient cohorts from Europe (Greece, Italy, the Netherlands, and Switzerland), the United States (2015-2024), and the United Kingdom (2020-2024). RESULTS In total, 2,493 patients were included (derivation, n = 573; validation n = 1,920). In a multivariable model for the derivation cohort, LS ≥ –9% and cardiac biomarkers at previously validated thresholds (NT-proBNP 332 ng/L and 8,500 ng/L and high-sensitivity troponin T ≥ 50 ng/L) were independent poor prognostic factors stratifying patients into stages I, II, IIIA, IIIB, and IIIC. In the validation cohort, the patient stages were stage I: 317 (17%), II: 782 (41%), IIIA: 551 (29%), IIIB: 174 (9%), and IIIC: 96 (5%), respectively (first-line daratumumab treated: 826; 43%). With a median follow-up of 34 months, median overall survival (OS) was not reached (NR); estimated 1-year, 2-year, and 3-year OS was 82%, 74%, and 70% respectively. The median survival for stages I to II, IIIA, IIIB, and IIIC were NR, 67, 26, and 7 months (1-year OS IIIC 53% v 68% for IIIB in the daratumumab-treated patients), respectively ( P < .001). External validation exhibited good predictive performance: 12-month calibration slope was 1.09, Harrell C 0.69, Royston D 1.19, and R 2 D 0.25. Stage IIIC independently discriminated the poorest outcome across all cohorts. CONCLUSION This defines and validates a new staging system from systemic AL amyloidosis with robust identification of an ultra-poor risk stage (IIIC) in contemporarily treated patients.
Lentiviral vectors engineered for direct In Vivo delivery to resting T cells
Nenavath, Gopal Naik, Hasan, Md Sharif, Ravichandran, Nainika, Kadungure, Tatenda, Gwilt, Collin, Kumar, Ajay , Jain, Pragati, Chin, Chia-Hsuan , Gromer, Kyle D., Alía, Miguel A Muñoz, Lech, Patrycja, Carey, Timothy S. , Kinney, Cheryl S., Salimi, Hamid , Peng, Kah-Whye , Ravichandran, Nainika, Krotova, Karina Y. , Packiriswamy, Nandakumar , Jain, Pragati, Vandergaast, Rianna , Feser, Colby J. , Carey, Timothy, Kinney, Christian

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5902-5902

10.1182/blood-2025-5902 Get It

Abstract Direct in vivo T cell engineering offers a new paradigm for CAR T delivery. We have evaluated several approaches to engineer lentiviral (LV) vectors capable of delivering CAR transgenes directly and selectively to T cells in vivo, within the lymphoid niche. Our goal was to develop an LV delivery platform that following intravenous administration can selectively bind and activate T cells, deliver and integrate the (CAR) transgene into genomic DNA, and drive CAR expression on the T cell surface. Further requirements were that the retargeted LV should be associated with minimal off-target transduction of tumor cells and normal host tissues and should be manufacturable at titers sufficient for human application. Our strategy for retargeting has been to modify the trimeric VSV-G protein, which is well established for efficient LV pseudotyping. Of the approaches evaluated, three retargeting platforms have proven to be effective: direct covalent display, indirect covalent display, and G-capping. Direct covalent display. This (LV-169) approach uses chimeric VSV-G protein that contains a CD3-targeting ligand displayed as a N-terminal extension of VSV-G protein that has been mutated to ablate (blind) its interaction with the LDL receptor. Chimeric and nonchimeric blinded G proteins are co- incorporated into LV particles within mixed envelopes which bind to CD3. Upon binding to cell surface CD3, the engineered particles activate T-cells and enter acidifying endosomes, whereupon they trigger membrane fusion and deliver their payloads. LV-169 displaying an anti-human CD3 scFv selectively transduced resting human T cells in PBMC cultures, in fresh human whole blood and following intravenous administration to humanized mice. In immunocompetent Cre reporter mice, surrogate vectors displaying anti-murine CD3 scFv selectively transduced lymph node resident T cells, with off-target transduction being limited to tissue-resident macrophages. To eliminate the incorporation of CAR protein into the LV-169 envelope, which can lead to highly undesirable transduction of tumor cells expressing the CAR target, we placed the CAR transgene in reverse to 5'LTR orientation, downstream of a T-cell specific promoter/enhancer. In vivo efficacy of LV-169-BCMA-CAR was demonstrated in humanized mice bearing disseminated OPM-2 myeloma tumors. Clinical translation of this construct is now underway. Indirect covalent display. In this G-protein engineering approach, a short peptide (SPY-tag) is displayed as an N-terminal extension of the LDLR-blinded VSV-G protein. The SPY-tagged LV vectors are then covalently modified to display a CD3-targeting ligand by simply mixing them at room temperature with a bifunctional fusion protein consisting of the SPY-catcher and the CD3 ligand. Under these conditions, the SPY-catcher and the SPY-tag spontaneously form a covalent isopeptide bond. The CD3 ligand-modified LV particles were shown to specifically activate and transduce T cells ex vivo within human PBMC cultures. G-capping. In the final approach, the VSV-G protein is not genetically modified. Instead, a “capping” protein crosslinker that binds directly to the unmodified G protein on preformed LV particles is used to mask their LDLR binding sites and redirect them to interact with CD3. Mixing of the CD3-targeted capping protein with traditional G-pseudotyped LV particles leads to efficient binding of the cap to the trimeric G proteins. The cap-modified LV are unable to interact with LDLR but interact efficiently with CD3. CD3-capped LV particles were highly specific and efficient in human T cell activation and transduction in PBMC cultures. The association between the G protein and the bound cap is highly stable during freeze-thaw cycles and at room temperature, a critical attribute of this platform to facilitate the manufacture of a clinically and commercially viable LV product. In summary, we have developed three translationally relevant platform technologies for the generation of LV particles capable of delivering CAR transgenes specifically and efficiently to resting niche-resident T cells after intravenous administration. Manufacturing studies are underway and, in the case of the LV-169 platform, clinical translation is already in progress.
Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)
Peres, Lauren C. , Shune, Leyla , Leitzinger, Christelle, Reid, Brett M. , Cassano, Raffaella Cassano , Kalariya, Nilesh, Gaballa, Mahmoud , Hunzeker, Zachary , Hosoya, Hitomi , Mikkilineni, Lekha , Gonzalez, Rebecca , Cahoon, Christopher, Sborov, Douglas W. , Bhurtel, Jenny , Purvey, Sneha , Ferreri, Christopher J. , Varga, Cindy , Voorhees, Peter M. , Goel, Utkarsh, Khouri, Jack , Afrough, Aimaz , Sannareddy, Aishwarya , Hassan, Hamza , Gordillo, Christian , Biran, Noa , Green, Kimberly , Zanwar, Saurabh , Costa, Luciano da Fontoura , Bal, Susan , Midha, Shonali , Alsina, Melissa , Shain, Kenneth H. , Kumar, Shaji , Patel, Krina, Sidana, Surbhi , Hansen, Doris, Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Dima, Danai , Colin, Christelle , Portuguese, Andrew J. , Banerjee, Rahul , Pasvolsky, Oren , Dillard, Christen , Grajales‐Cruz, Ariel , Puglianini, Omar Castañeda , Nishihori, Taiga , Wagner, Charlotte B , Kort, Jeries , Geer, Marcus , Atrash, Shebli , Goel, Utkarsh , Raza, Shahzad , Anwer, Faiz , Anderson, Larry D. , Herr, Megan M. , Reshef, Ran , Zolotov, Eli , Biran, Noa , Davis, James, Green, Kimberly, Lin, Yi , Costa, Luciano, Nadeem, Omar , Baz, Rachid , Locke, Frederick L. , Patel, Krina K. , Hansen, Doris K.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4000-4000

10.1182/blood-2025-4000 Get It

Abstract Introduction: Cilta-cel is a BCMA-directed CAR T-cell therapy that has shown remarkable efficacy in patients with RRMM. As real-world (RW) experience with cilta-cel continues to expand, and with the recent FDA guidance reducing the recommended proximity to the CAR T center from four to two weeks post-infusion, there is growing interest in identifying patients at low risk for severe early complications who may be safely managed in the outpatient setting and potentially ‘discharged’ home earlier. Methods Data were collected from 769 patients with RRMM treated with cilta-cel at 15 institutions in the U.S. via the Multiple Myeloma Immunotherapy Consortium.Logistic regression was used to identify predictors of patients who could be managed in the outpatient setting (low-risk group). Based on expert consensus within the Consortium, low-risk patients were defined as: grade ≤1 CRS, no ICANS, and no IEC-HS. The remaining patients were categorized as high-risk. We evaluated baseline characteristics with missingness &lt; 20% as predictors, including age, sex, race, and ethnicity, ECOG performance status (PS) at time of lymphodepletion (LD), extramedullary disease, bone marrow plasma cell (BMPC) percentage, high-risk cytogenetics, bridging therapy including response, penta-refractory status, number of prior lines of therapy, prior anti-BCMA therapy, baseline C-reactive protein (CRP), and baseline ferritin. The cohort was restricted to patients with complete data on all predictors (n=455) and split into a training and testing cohort (80/20 split, n=364/91). Bidirectional stepwise regression was used to build the predictive model using variables with significance of p&lt;0.15 selected for entry. The best model was selected based on the AIC (Akaike Information Criterion) and a significance level of p&lt;0.05. Results Among the 455 patients with complete data included in the final model, 290 (64%) were categorized as low-risk and 165 (36%) as high-risk. Compared to the low-risk group, high-risk patients were more likely to have an ECOG PS ≥2 at time of LD (20% vs 9%, p&lt;0.001), high-risk cytogenetics (47% vs 35%, p=0.009), and penta-refractory disease status (34% vs 24%, p=0.031). High-risk patients also had a higher median BMPC percentage (15% vs 5%, p&lt;0.001), and higher baseline pre-LD CRP and ferritin. Overall response rates were high, at 95% vs 90% (p=0.047) for the low vs high risk groups, with complete response or better achieved in 73% vs 66% of patients, respectively (p=0.14). With a median follow-up of approximately 11 months, median progression-free survival was not reached (95% CI: 27-NA) in the low-risk group and 18.2 months (95% CI: 13.1-NA) in the high-risk group. In terms of safety, non-ICANS neurotoxicity (NINT) occurred less frequently in the low-risk group (6.6% vs 13%, p=0.015). Specifically, Parkinsonism was observed in 1.7% vs 6.1% (p=0.013), and cranial nerve palsy in 4.5% vs 5.5% (p=0.7), respectively. Non-relapse mortality (NRM) was lower in the low-risk group (4.2%) compared to the high-risk group (14%; p &lt; 0.001). The most common causes of NRM in the low- and high-risk groups were acute toxicities (0% vs 36%, including CRS, IEC-HS, and ICANS), delayed toxicities (0% vs 8%, including colitis, NINT, and Parkinsonism), infections (50% vs 48%), and other unrelated causes (50% vs 8%). The best model to predict low-risk patients that could be managed in the outpatient settingincluded BMPC percentage and ECOG PS at LD. In the training cohort, patients with a higher pre-LD BMPC percentage and an ECOG PS ³2 were less likely to be in the low-risk group(OR per 1-unit change in BMPC percentage = 0.99, 95% CI=0.98-0.99, p&lt;0.001 and OR for ECOG PS 2-4 = 0.38, 95% CI=0.20-0.72, p=0.003). The AUC for this model was 0.663 in the training cohort and 0.659 in the testing cohort. Conclusion In this large, multi-institutional cohort of patients with RRMM treated with cilta-cel, we identified clinical factors associated with lower risk for early severe toxicities, supporting outpatient administration and the potential for earlier discharge in selected patients, particularly those who are fit and have low disease burden. Our findings provide a practical framework to guide risk stratification and outpatient CAR T management strategies, particularly in light of evolving regulatory guidance and growing RW experience with cilta-cel.
MAPS-R: International consensus classification-guided revision of the mayo alliance prognostic system for systemic mastocytosis
Tefferi, Ayalew , Aperna, Fnu, Kumar, Mahesh, Abdelmagid, Maymona, Butterfield, Joseph H. , Pongdee, Thanai , Reichard, Kaaren K. , Gangat, Naseema , Pardanani, Animesh , Yi, Cecilia Arana , Arber, Daniel A. , Orazi, Attilio , Chen, Dong

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2017-2017

10.1182/blood-2025-2017 Get It

Abstract Background: The International Consensus Classification (ICC) for systemic mastocytosis (SM) recognizes mast cell leukemia (MCL) and SM with associated myeloid neoplasm (SM-AMN) as distinct categories of advanced SM (SM-Adv; Arber et al. Blood 2022;140:1200). Contemporary risk models in SM, including the Mayo Alliance Prognostic System (MAPS), do not account for the prognostic heterogeneity among ICC-defined SM-Adv subcategories. Methods: Mayo Clinic databases were utilized to access patient information. Diagnoses of SM and its morphological subcategories were confirmed through clinical evaluations and review of BM pathology. Diagnostic criteria were retrospectively fitted to be consistent with those of the ICC (Arber et al. Blood 2022;140:1200); diagnosis of MCL required the presence of immature cytomorphology of mast cells and only myeloid neoplasms were listed under the category of SM-AMN.Next-generation sequencing and cytogenetic studies was performed in a subset of the study patients according to previously described methodologies. Statistical analyses were conducted on clinical and laboratory data collected at the time of initial diagnosis while survival analysis was censored at the time of allogeneic stem cell transplant (ASCT). Results: A total of 910 Mayo Clinic patients with SM (median age 56 years, range 12-89; males 50%) were accessed in order to conduct a series of multivariable analyses (MVA) in search of independent risk factors for transplant-censored overall survival (OS). All patients were evaluable for assignment to specific ICC categories of SM: indolent (ISM; N=553), aggressive (ASM; N=114), SM-AMN (N=235), and MCL (N=8); the AMN components in SM-AMN included acute myeloid leukemia (N=18), chronic myelomonocytic leukemia (N=70), myelodysplastic syndromes (N=32), MDS/myeloproliferative overlap (N=81), myelofibrosis (N=7), polycythemia vera or essential thrombocythemia (PV/ET; N=19), and others (N=8). In addition, subsets of patients were evaluable for hemoglobin level (N= 865), white blood cell count (WBC; N=858), platelet count (N= 859), serum alkaline phosphatase (ALP; N=761), serum tryptase level (N=706), karyotype (N=574), and mutations (N=240). Median follow-up for living patients was 70 months (range, 0-520); during this time 346 (38%) deaths, 16 leukemic transformations, and 20 ASCTs were documented. ROC analysis-determined optimal cutoff levels for predicting OS included age at ≥60 years, platelet count &lt;150 x 109/L, tryptase level ≥100 ng/mL, WBC ≥10 x 109/L, hemoglobin below sex-adjusted lower limit of normal (anemia), and ALP &gt;210 U/L in women or &gt;170 U/L in men (increased). All except WBC ≥10 x 109/L retained significance during MVA that included ICC-specified SM categories: MCL (HR 74.8, 26.0-215.3; p&lt;0.01); SM-AMN (HR 3.9, 2.5-6.0; p&lt;0.01); ASM (HR 2.2, 1.4-3.5; p&lt;0.01); age ≥60 years (HR 3.3, 2.2-4.7; p&lt;0.01); platelets &lt;150 x 109/L (HR 2.8, 2.0-3.9; p&lt;0.01); tryptase ≥100 ng/mL (HR 2.1, 1.5-2.9; p&lt;0.01); anemia (HR 1.7, 1.1-2.4; p&lt;0.01); and increased ALP (HR1.5, 1.1-2.0; p=0.01). A subsequent HR-weighted risk model effectively delineated 5 risk levels ranging in median survivals from 11 months to 372 months (Figure 1). Figure 2 outlines complementary subtype-specific risk models; to that end, risk factors for ISM included age ≥60 years (HR 4.5, 2.5-7.9), tryptase ≥100 ng/mL (HR 3.5, 2.1-6.0); platelets &lt;150 x 109/L (HR 3.4, 1.5-7.9), and anemia (HR 2.4, 1.2-4.8); for ASM age ≥60 years (HR 2.3, 1.3-4.3), platelets &lt;150 x 109/L (HR 2.4, 1.4-4.0), and anemia (HR 2.0, 1.2-3.4); and for SM-AMN age ≥60 years (HR 2.9, 1.6-5.2), platelets &lt;150 x 109/L (HR 2.5, 1.6-3.9), and tryptase ≥100 ng/mL (HR 2.5, 1.6-3.9) [Figure 2]. In SM-AMN, additional prognostic relevance from subcategorization into PV/ET vs. all other types of AMN was appreciated (Figure 3; HR 4.0, 1.6-3.9) and incorporated into the risk model for SM-AMN (Figure 2). Abnormal karyotype (AK) and high risk mutations(HRM; ASXL1, SRSF2, RUNX1, NRAS)clustered withSM-AMN with AK and ASXL1MUT displaying independent prognostic relevance that was most apparent in SM-AMN. Conclusions : MAPS-R relies on the prognostic eminence of ICC-defined morphologic subcategories and allows for additional SM subtype-specific risk stratification. SM associated with ET or PV is a prognostically unique subcategory of SM-AMN and should be recognized as such in future classification schemes. SM-AMN must be thoroughly ruled out in the presence of AK or HRM.
Hematological symptom burden and treatment patterns in patients with IgG4-related disease: A real-world, multicenter retrospective analysis
Vojjala, Nikhil, Gillani, Syed Fahad, Shah, Rushi, Kotla, Nikhil Kumar, Mahadevia, Himil, Valasapalli, Srijan, Krishnamoorthy, Geetha, Singh, Vijendra, Vojjala, Nikhil, Gillani, Syed Fahad, Shah, Rushi, Kotla, Nikhil Kumar, Mahadevia, Himil, Valasapalli, Srijan, Krishnamoorthy, Geetha, Singh, Vijendra

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4479-4479

10.1182/blood-2025-4479 Get It

Abstract Background: IgG4-related disease (IgG4-RD) is a rare, immune-mediated fibroinflammatory condition characterized by tissue infiltration with IgG4-positive plasma cells. While solid organ involvement is well documented, data on hematologic manifestations and associated outcomes remain limited. Understanding hematological burden and real-world treatment patterns is essential to guide comprehensive management. Methods: We conducted a multicenter, retrospective cohort study using the TriNetX Research Network, comprising electronic health records from multiple U.S. healthcare systems. Adults (≥18 years) with a diagnosis of IgG4-RD (ICD-10 codes) were included. Patients with a prior diagnosis of hematologic malignancy were excluded. Demographic characteristics, hematologic manifestations, treatment patterns, and overall mortality were assessed. The median follow-up duration was 519 days. Results: A total of 2,596 patients with IgG4-RD were identified, of whom 554 (21.3%) exhibited at least one hematologic manifestation. The mean age was 58.1 ± 15.9 years; 53% were male (n=1,379), and 57% were White (n=1,492). Hypertension was the most common comorbidity (44%, n=1,136). Among those with hematologic involvement, key manifestations included lymphadenopathy (n=605, 23.3%), hepatomegaly (n=114, 4.4%), splenomegaly (n=73, 2.8%), eosinophilia (n=71, 2.7%), pancytopenia (n=31, 1.2%), hypergammaglobulinemia (n=71, 2.7%), and monoclonal gammopathy (n=86, 3.3%). Regarding outcomes, 127 of 2,596 patients (4.9%) died during the follow-up period. Among those with hematologic manifestations, 36 of 554 (6.5%) died, indicating a numerically higher mortality rate in this subgroup. Treatment data revealed that all patients received corticosteroids as initial therapy. Additionally, 531 patients (20.4%) received steroid-sparing immunosuppressants. The most used agents included rituximab (6%), azathioprine (6%), mycophenolate mofetil (5%), and methotrexate (3%). Conclusion: In this large, real-world cohort of patients with IgG4-RD, hematologic manifestations were observed in over one-fifth of patients and were associated with a numerically higher mortality rate. Lymphadenopathy was the most common hematologic feature. Despite the widespread use of corticosteroids, a substantial proportion of patients required steroid-sparing agents. These findings highlight the hematologic complexity of IgG4-RD and underscore the need for multidisciplinary management and prospective studies focused on hematologic outcomes.
A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia
Thompson, Meghan, Mato, Anthony, Palomba, Lia, Leslie, Lori, Derkach, Andriy, Nemirovsky, David, Islam, Prioty, Geyer, Mark, Caron, Philip, Goldberg, Aaron, Kumar, Anita, Moskowitz, Alison, Lue, Jennifer, Owens, Colette, Salles, Gilles, Stein, Eytan, Steiner, Raphael, Torka, Pallawi, Dahncke, Lori, Ordona, Emily, Meem, Mashiyate, Hutzler, Claire, Harris, Miranda, Shah, Monica, Karnam, Megha, Nogan, Lauren, Maloney, Caitlin, Shah, Anmol, Nyima, Tenzin, Dorsey, Colleen, Doyle, Kate, Howgate-Klingaman, Jennifer, Brutus, Jamila, Tyznar, Dianna, Lincke, Anna, Wray, Rick, Feldman, Tatyana, Zelenetz, Andrew, Roeker, Lindsey, Thompson, Meghan, Mato, Anthony, Palomba, Lia, Leslie, Lori, Derkach, Andriy, Nemirovsky, David, Islam, Prioty, Geyer, Mark, Caron, Philip, Goldberg, Aaron, Kumar, Anita, Moskowitz, Alison, Lue, Jennifer, Owens, Colette, Salles, Gilles , Stein, Eytan, Steiner, Raphael, Torka, Pallawi, Dahncke, Lori, Ordona, Emily, Meem, Mashiyate, Hutzler, Claire, Harris, Miranda, Shah, Monica, Karnam, Megha, Nogan, Lauren, Maloney, Caitlin, Shah, Anmol, Nyima, Tenzin, Dorsey, Colleen, Doyle, Kate, Howgate-Klingaman, Jennifer, Brutus, Jamila, Tyznar, Dianna, Lincke, Anna, Wray, Rick, Feldman, Tatyana, Zelenetz, Andrew, Roeker, Lindsey

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5676-5676

10.1182/blood-2025-5676 Get It

Abstract Background: Advantages of covalent Bruton Tyrosine Kinase inhibitor (cBTKi) treatment (tx), as compared to BCL2 inhibitor (BCL2i) containing regimens, include ease of initial administration without a requirement for frequent laboratory monitoring, even in patients (pts) with bulky disease. However, limitations of cBTKi monotherapy include acquired resistance, cumulative toxicity and the financial burden associated with continuous administration. CLL pts treated on the E1912 study who discontinued (dc) ibrutinib for reasons other than progression of disease (PD) had a median progression free survival (PFS) of ~2.7 years from ibrutinib dc, suggesting that a time-limited cBTKi strategy may be feasible for some pts(Shanafelt et al. Blood Advances 2025). We hypothesized that acalabrutinib (acala) and obinutuzumab (O) could be administered as a time-limited initial tx for CLL with duration guided by minimal residual disease (MRD). Methods: This is an ongoing phase II, multicenter, investigator-initiated study of acala and O for previously untx pts with CLL/small lymphocytic lymphoma (SLL) requiring tx per iwCLL 2018 criteria (NCT04722172). Pts with TP53 aberrancy are excluded. Pts receive acala 100 mg twice daily and O during 28-day cycles (C) 2-7. Undetectable MRD is defined with a 10-4 sensitivity in the peripheral blood (PB) by ClonoSeq next generation sequencing (uMRD4). Pts undergo MRD testing at C13; if uMRD4 at C13 with a complete response (CR) or partial response (PR), pts dc acala and enter tx free observation (TFO). If detectable MRD4 (dMRD4) at C13, pts continue acala until uMRD4, with repeat MRD testing occurring at C16, 19, 22 and 25. All pts dc acala after a maximum of 26C and enter TFO, even if dMRD4. If pts have PD meeting iwCLL criteria for tx during TFO, re-tx consists of acala + 6 cycles of O. Pts are followed for 13C of re-tx. Primary endpoint is 36-month PFS. Results: 55 pts initiated tx. Baseline characteristics include: median age 67, 64% male, 47% LN ≥ 5 cm, 73% IGHV unmutated. Best overall response rate (ORR) was 95% (CR: 4, PR: 48, SD: 0, PD: 1, unknown: 2). Best uMRD4 rate at any time during the study was 49% (n=27 pts, intention-to-treat, IIT). 5 pts dc tx prior to C13 MRD testing (2 pt decision, 2 AE, 1 due to PD after ~4C). At C13, 22 pts (40% of IIT) were uMRD4; 21 entered TFO after 13C and 1 pt had 19C tx prior to TFO. 28 pts had dMRD4 (51% ITT) at C13. Between C13 and 26, 2 pts became uMRD4 and entered TFO, 1 pt died (COVID-19), and 2 pts stopped acala for tx of other cancers. 21 pts completed 26C acala per protocol prior to entering TFO; 2 additional pts had PD at C25 and EOT. Median tx duration was 19C. In univariate analyses, age, del11q, del13q, IGHV mutational status and baseline LN ≥ 5 cm were not predictive of uMRD4 at C13. At a median follow-up of 38 months, the median PFS for the overall cohort is 42 months (95% confidence interval (CI): 37, not reached), with an estimated 36-month PFS of 69% (95% CI: 57%, 84%). At data cutoff, of 46 pts entering TFO, 29 pts remained in TFO without PD, 7 pts had PD during TFO but had not met iwCLL criteria for re-tx, and 10 pts had PD requiring tx (5 pts re-tx pe protocol, 5 came off study for non-protocol tx approach). The overall median TFO period (measured from acala dc to PD) was 25 months (95% CI: 21 – not reached, n=46 pts). 5 pts have initiated re-tx with acala + O (1 pt best response PR and uMRD4; 4 ongoing tx). Median time to re-tx was 18 months (range 6-34, n=5 pts). Conclusions: This study is proof-of-concept that cBTKi may be administered as a time-limited tx without the addition of a BCL2i. While the initial PFS is shorter than historical studies examining continuous cBTKi, of patients entering TFO after 1-2 years of acala, the median duration of TFO until PD is 25 months, and longer follow-up will provide re-tx outcomes. Potential advantages to MRD-guided, time-limited cBTKi tx include time off tx for pts, limiting acquired resistance, the ability to re-challenge with cBTKi at progression, and reserving BCL2i for third-line or later tx.
AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning
Corraes, Andre De Menezes Silva , Shaw, Monica , Holmes, Lucy , Burgstahler, Allison, Riester, Kimberly, Jankowski, Matthew, Hampel, Paul J. , Kapoor, Prashant , Khurana, Arushi , Kourelis, Taxiarchis , Leung, Nelson , Warsame, Rahma , Kumar, Shaji , Ansell, Stephen M. , Johnston, Patrick B. , Guzman, Emmanuel Contreras , Shaw, Monica, Holmes, Lucy, Burgstahler, Allison, Mclean, Jody, Villasboas, José C. , Bennani, N. Nora , Binder, Moritz , Gertz, Morie A. , Kenderian, Saad S. , Cook, Joselle , Shah, Meera , Alkhateeb, Hassan B. , Wang, Yucai , Durani, Urshila , Paludo, Jonas , Lin, Yi

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6131-6131

10.1182/blood-2025-6131 Get It

Abstract Introduction: CAR-T therapy has transformed cancer therapy. with its first Food and Drug Administration (FDA) approved product in August 2017. Given the expanding indications and growing experience, particularly with management of immediate toxicities requiring specialized expertise such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity syndrome (ICANS), FDA recently removed the Risk Evaluation and Mitigation Strategies (REMS) for CD19 and BCMA targeting CAR-T on June 26th2025. In particular, given that CRS and ICANS typically occur in the first 2 weeks post CAR-T infusion, the minimum required stay near CAR-T treatment center is reduced from one month to 2 weeks. While this could reduce treatment burden for patients (pts) who need to travel away from home to receive CAR-T, there is a need to update the transition of care from CAR-T center to pts' local oncology practice. Pts carry in their rate of recovery and have varying supportive care needs in the second half of the month post CAR-T infusion. To assist with care transition and planning, we examine the use of AI multimodal large language model (LLM) to predict patients' supportive care needs 2 weeks after CAR-T infusion based on the clinical data at the time of CAR-T evaluation, prior to leukapheresis. This timepoint was selected to also maximize travel, lodging and caregiver planning for pts and family as well. Methodology: Pts who were treated with FDA-approved CAR-T at Mayo Clinic Rochester between December 2022 and June 2025 were examined. Based on experiences with referral practices in the Midwest region, we defined patients with high monitoring needs as those who between day 14-30 post CAR-T had either hospital admission due to recurrent CRS or ICANS or required transfusion of more than 1 blood product per week (red blood cell or platelets). Others were classified as low monitoring needs. Clinical notes, labs, vital signs and electrocardiogram at the time of CAR-T evaluation were abstracted and summarized by Gemini LLM for association with patients with high versus low monitoring needs post CAR-T. Model was developed and tested for predicted needs and concordance with actual outcome of these pts. Results: Among the 362 pts who received FDA approved CAR-T in the timeframe, 84 pts had high monitoring needs. An additional 84 pts with low monitoring needs were randomly selected from 278 pts. These were divided into a training cohort and test cohort of 84 pts each, with 42 pts with high and 42 pts with low monitoring needs. Demographics of the two cohorts displayed no statistical difference. LLM analysis of the clinical data at the time of CAR-T eval identified 5 categories associated with risk for high monitoring needs: 1) Disease status (clinical notes about bulky, progressive disease or CNS involvement); 2) inflammatory and tumor burden markers (CRP, LDH); 3) hematologic status (platelet, plt; neutrophil count ANC); 4) renal function; 5) performance status. Using common clinical lab parameter convention (platelets &lt;100, ANC&lt; 1, CrCl&lt; 30ml/min), and prioritizing for not missing pts with high monitoring needs, LLM model was defined to predict patients for high monitoring needs if high risk feature was identified in category 1 or any category combinations; whereas patients with no high risk feature or only 1 category that is not disease status was predicted as low monitoring needs. In this model, the sensitivity was 85.7%, specificity 23.8%, F1 score 65.5%. Applying this model to test cohort 2, the sensitivity was 83.3%, specificity 28.6%, and F1 score 65.4%. Discussion: We demonstrate proof-of-concept that LLM can be used to analyze clinical data at the time of evaluation for CAR-T eligibility to predict for supportive care needs post treatment. Not surprisingly, features identified by LLM to be associated with high monitoring needs are those previously reported by us and others at the time of CAR-T evaluation and or pre-lymphodepletion to be associated with risk for cytopenia, infection, hospitalization and non-relapse mortality. Based on the summary output generated by LLM, additional opportunities for classification methods were identified to improve specificity and balanced accuracy of the LLM model. This is a promising tool for further development to assist clinicians and patients to plan their treatment journey.
Anti-platelet factor 4 antibodies in MGUS-related thrombosis
Kanack, Adam J. , Splinter, Noah P., Mauch, Emily, Leger, Rachel, Shah, Surbhi , Kumar, Shaji , Pruthi, Rajiv K. , Padmanabhan, Anand , Houghton, Damon E. , Dispenzieri, Angela , Chen, Dong

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 1321-1321

10.1182/blood-2025-1321 Get It

Abstract Introduction: Monoclonal gammopathy of thrombotic significance (MGTS) is a recently recognized thrombophilia where monoclonal platelet factor 4 (PF4)-specific IgG antibodies initiate a chronic prothrombotic state characterized by recurrent and potentially life-threatening thrombosis. Studies from large data sets demonstrate that patients with monoclonal gammopathy of undetermined significance (MGUS) have a heightened risk of experiencing thromboembolic events without a precise explanatory mechanism. The prevalence of MGTS in MGUS-related thrombosis is unknown; however, the recent identification of MGTS antibodies as a cause of thrombosis suggests a potentially causative mechanism. Emerging evidence indicates that detecting pathogenic MGTS antibodies presents diagnostic challenges due to the insensitivity of FDA-approved diagnostic assays adopted from HIT (HIT ELISAs) and gold-standard functional tests that use heparin-treated platelets, such as the serotonin release assay (SRA). Only PF4-enhanced functional assays, including the PF4-dependent P-selectin expression assay (PEA) and PF4-SRA, have proven sensitive for detecting MGTS antibodies. In this study, the PEA was utilized to better define the incidence of pathogenic anti-PF4 antibodies among a cohort of MGUS patients with a history of thrombosis. Methods: A search of the Mayo Clinic Dysproteinemia Bank was conducted to identify two cohorts of IgG MGUS patients, one with venous thromboembolism-associated diagnosis code(s) and the other without. A diagnosis of multiple myeloma was exclusionary. Each serum sample was assessed using the PEA. Mayo Clinic's Institutional Review Board approved the research study. Results: Among the 134 patients studied in the thrombosis cohort, 17 (13%) stimulated platelet activation in the PEA (positive cut-off ≥19%), some weakly. Of these, four patients (Patients 1-4) were confirmed to have PF4-dependent platelet-activating antibodies inhibitable with high concentrations of heparin and sensitive to blockade of the IgG receptor on platelets, FcGRIIa. The thrombotic complications experienced included recurrent deep venous thrombosis (DVT) over several years (Patient 1), a single DVT (Patient 2), a thrombotic cerebrovascular accident (CVA) (Patient 3), and a series of thrombotic events, including DVTs, left atrial thrombosis, pulmonary embolism, and acute limb ischemia (Patient 4). Notably, longitudinal samples spanning twelve years (Patient 1), six years (Patient 2), three years (Patient 3), and on a single sample date (Patient 4) were confirmed positive by PEA. The prolonged persistence of platelet-activating anti-PF4 antibodies in Patients 1-3 supported a diagnosis of MGTS in these patients. Strikingly, all four patients tested negative in two FDA-approved HIT ELISAs (Immucor PF4 IgG and Zymutest HIA IgG). SRA was negative for Patients 1 and 2, weakly positive for Patient 3 (33%), and positive for Patient 4 (72%). Of the 166 patients in the MGUS minus thrombosis cohort, one patient demonstrated a non-heparin induced HIT-like antibody that was HIT ELISA (Optical Density &gt;1.0) and PEA-positive, and inhibitable using high concentrations of heparin and FcGRIIa blockade. No follow-up samples were available to assess antibody longevity. The patient had no history of thrombosis, and testing demonstrated that the anti-PF4 antibody was not synonymous with the MGUS antibody.Conclusions: Among a cohort of 134 MGUS patients with thrombosis, the prevalence of MGTS was found to be 2.2% (3 patients with persistent platelet-activating anti-PF4 antibodies). The identification of anti-PF4 antibodies among MGUS patients provides a mechanism contributing to the increased thrombotic risk associated with monoclonal gammopathies. Antibody negativity in HIT ELISA and variable positivity in the SRA highlight the nonclassical serology associated with anti-PF4 antibodies in MGTS and support performing PF4-enhanced functional testing. In addition, some patients appear to produce coincidental (non-monoclonal) platelet-activating anti-PF4 antibodies without evidence of thrombosis, although the longevity of such antibodies could not be examined in the one patient where it was identified. These findings highlight the need for larger, prospective MGUS studies to validate these observations, further define the interplay between monoclonal gammopathies and thrombotic risk, and to better understand the long-term outcomes of patients with MGTS.
Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey
Hydren, Jay, Jensen, Rachel, Martinez, Jorge Arturo Hurtado, Ahlstrom, Jennifer, Barnes, Mason, Costello, Caitlin, Kaur, Gurbakhash, Mohan, Meera, Cottini, Francesca, Sborov, Douglas, Kumar, Shaji, Raje, Noopur, Moreau, Philippe, Deshpande, Maithili, Gupta-Werner, Niodita, Blanc, Tonya Le, Fowler, Jessica, Banerjee, Rahul, Hydren, Jay, Jensen, Rachel, Martinez, Jorge Arturo Hurtado, Ahlstrom, Jennifer, Barnes, Mason, Costello, Caitlin, Kaur, Gurbakhash, Mohan, Meera, Cottini, Francesca, Sborov, Douglas, Kumar, Shaji, Raje, Noopur, Moreau, Philippe, Deshpande, Maithili, Gupta-Werner, Niodita, Blanc, Tonya Le, Fowler, Jessica, Banerjee, Rahul

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6354-6354

10.1182/blood-2025-6354 Get It

Abstract Background Teclistamab (Tec) and Talquetamab (Tal) are the two first FDA approved bispecific antibodies (BsAb) for the treatment of patients (pts) with relapsed/refractory multiple myeloma (RRMM). Both Tec and Tal should be initiated with step-up dosing (SUD) in an inpatient (IP) setting to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), per US label. However, standard of care practice continues to evolve and more pts receive SUD as an outpatient (OP) to reduce healthcare resource utilization and improve pt convenience. While most real-world evidence has focused on clinical and safety outcomes of pts treated with Tec and Tal, pt experience associated with these novel BsAb therapies is relatively unexplored. Methods HealthTree Foundation, a multiple myeloma pt advocacy group which provides enrolled pts with information on treatments, community groups, and research participation, surveyed RRMM patients who have received Tec or Tal. Eligible pts who completed the treatment experience survey had at least 4 months of follow-up after starting BsAb. The survey was fielded from May 2024 through June 2025. Data collection followed IRB-exempt protocols with informed consent. Results A total of 32 patients (24 Tec, 8 Tal) completed the survey. The median age was 70 years, 50% were male, and 84% were white. Most pts (n=24; 75%) received SUD at their primary oncology clinic (n=19, 59% at an academic center; n=5, 16% at local community center), and 8 (25%) at an academic center which was not their primary oncology clinic. All pts who received SUD at an academic center that was not their primary oncology clinic later transitioned to their local community clinic post-SUD and reported being satisfied or very satisfied with their transition of care experience. Overall, most pts (n= 21; 66%) received their entire step-up dosing during a single hospitalization, while some (n=6; 19%) received all doses of the SUD during separate hospitalizations for each dose. About 13% (n=4) received all SUD in an OP setting, and 3% (n=1) received SUD in a hybrid setting (mix of IP and OP). Although 85% (n=27) of the pts received IP SUD, 66% (n=21) would have preferred IP SUD in one hospitalization, while the remaining 34% (n=11) would have preferred OP or hybrid SUD. Among pts who received IP SUD (n=27), almost a quarter reported a preference for either OP (n=4; 15%) or hybrid SUD (n=2; 7%) and 78% (n=21) preferred one IP hospitalization for SUD. The factors influencing their preference for the setting of SUD in this IP sub-group were feeling more secure with IP monitoring (78%), convenience (26%), less worry about staying near healthcare centers (15%), being able to stay with their local physician (11%), staying closer to home (7%), and lower costs to the pt (4%). Among pts receiving OP SUD (n=4), 75% (n=3) preferred fully OP SUD and 25% (n=1) preferred hybrid SUD because of convenience (n=2; 50%), lower cost to pt (n=1; 25%), flexible dosing schedule (n=1; 25%), and feeling of security with IP monitoring (n=1; 25%). All the pts receiving hybrid SUD (n=1) preferred fully OP SUD due to convenience. Although Tec and Tal are subcutaneous (SC) injections, when patients were asked to compare the options of BsAbs with comparable efficacy and safety profile, they favored SC injection (n= 22; 69%) over intravenous infusion (n = 3; 9%), while 22% (n=7) had no preference for mode of drug administration. The challenges that impacted pt experience with Tec or Tal were treatment side effects (Tal pts: n=6, 75%; Tec pts: n=9, 38%) and distance or travel time to the treatment facility (Tal pts: n=2, 25%; Tec pts: n=4; 17%). Other reasons included caring for others, continuing to work, cost and insurance, lack of caregiver/care partner, being away from home, unavailability of the therapy in community setting near home, and eligibility criteria. Conclusions Most pts in this study received SUD at their primary oncology clinic. While most pts received IP SUD and preferred a single planned IP visit, one third preferred OP or hybrid SUD due to convenience. As the field moves toward OP-only SUD, this study underscores the need to consider pt preferences. There is an unmet need for community clinics providing SUD options closer to pt homes.